ArticleClinical and experimental medicine2025
Development and validation of a prediction model for cholangitis after percutaneous transhepatic cholangioscopic lithotripsy.
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Cholangitis is a common complication of percutaneous transhepatic cholangioscopic lithotripsy (PTCSL) for hepatolithiasis, but risk assessment tools are lacking. This study aimed to identify predictors of cholangitis after PTCSL and develop a predictive nomogram. This retrospective study analysed 245 patients who underwent 450 PTCSL sessions between 1 January 2016 and 1 January 2024. All sessions demonstrating cholangitis complications were classified into the cholangitis group, while the remaining sessions were classified into the non-cholangitis group. All the sessions were divided into training and validation sets. Least absolute shrinkage and selection operator (LASSO) analysis was conducted to preliminarily select predictors of cholangitis complications. Multivariable logistic regression was performed to identify factors for constructing the nomogram. Cholangitis was diagnosed in 51 patients (62 sessions), for an incidence of 13.78% (62 among 450 sessions). Three characteristic variables were included in the model: operation technique (odds ratio [OR] = 0.235, 95% confidence interval [CI]: 0.105-0.524, p < 0.001), globulin (OR = 1.077, 95%CI:1.026-1.131, p = 0.003), and postoperative prophylactic dexamethasone (OR = 0.286, 95%CI:0.145-0.564, p < 0.001). The area under the curve (AUC) for the nomogram was 0.749 (95% CI, 0.673-0.826) in the training set and 0.721 (95% CI, 0.593-0.849) in the validation set, demonstrating relatively high discriminability. The calibration curves demonstrated the consistency between the predicted and actual values. Decision curve analysis indicated that the nomogram offers net clinical benefits. Operation technique, globulin, and postoperative prophylactic dexamethasone may predict cholangitis after PTCSL. We developed a nomogram to estimate the risk of post-PTCSL cholangitis, which demonstrated good predictive performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.